## Nicholas J Slevin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4008212/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.4	349
2	Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncology, 2006, 42, 759-769.	0.8	204
3	Clinico-pathological and treatment-related factors influencing survival in parotid cancer. British Journal of Cancer, 1999, 80, 1296-1300.	2.9	142
4	Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. International Journal of Radiation Oncology Biology Physics, 1998, 40, 319-329.	0.4	136
5	Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. British Journal of Cancer, 2015, 113, 886-893.	2.9	136
6	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 2013, 13, 84.	1.1	113
7	A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clinical Oncology, 1996, 8, 297-307.	0.6	112
8	A systematic review of honey uses and its potential value within oncology care. Journal of Clinical Nursing, 2008, 17, 2604-2623.	1.4	108
9	Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: A retrospective review. Radiotherapy and Oncology, 2006, 78, 152-158.	0.3	97
10	Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiotherapy and Oncology, 1998, 48, 15-21.	0.3	92
11	Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. Radiotherapy and Oncology, 2003, 68, 105-111.	0.3	91
12	A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. British Journal of Oral and Maxillofacial Surgery, 2012, 50, 221-226.	0.4	82
13	Hypoxia in head and neck cancer. British Journal of Radiology, 2006, 79, 791-798.	1.0	76
14	Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head and neck and neck. Head	0.9	76
15	Monitoring Dosimetric Impact of Weight Loss With Kilovoltage (KV) Cone Beam CT (CBCT) During Parotid-Sparing IMRT and Concurrent Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, e375-e382.	0.4	71
16	Prediction of post-treatment trismus in head and neck cancer patients. British Journal of Oral and Maxillofacial Surgery, 2012, 50, 328-332.	0.4	71
17	NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer. Clinical Oncology, 2014, 26, 344-347.	0.6	70
18	Nasopharyngeal Carcinoma – A Retrospective Review of Demographics, Treatment and Patient Outcome in a Single Centre. Clinical Oncology, 2013, 25, 171-177.	0.6	64

#	Article	IF	CITATIONS
19	Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. British Journal of Oral and Maxillofacial Surgery, 2011, 49, 510-515.	0.4	63
20	Perfusion Estimated With Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely With Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1176-1183.	0.4	63
21	Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. Radiation Oncology, 2014, 9, 173.	1.2	63
22	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: A cohort study based on 994 patients. Radiotherapy and Oncology, 2011, 100, 108-115.	0.3	62
23	Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. , 2007, , CD006205.		60
24	Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada. Radiotherapy and Oncology, 1994, 31, 14-22.	0.3	59
25	Effect of Epoetin Alfa on Survival and Cancer Treatment–Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 5751-5756.	0.8	58
26	The Prognostic Significance of the Biomarker p16 in Oropharyngeal Squamous Cell Carcinoma. Clinical Oncology, 2013, 25, 630-638.	0.6	53
27	Radiotherapy for pleomorphic adenoma of the parotid gland. International Journal of Radiation Oncology Biology Physics, 1992, 22, 925-928.	0.4	52
28	Carcinoma of the hard palate treated with radiotherapy: a retrospective review of 31 cases. Oral Oncology, 2001, 37, 493-497.	0.8	52
29	Radiotherapy for head and neck cancer in elderly patients. Radiotherapy and Oncology, 2003, 69, 37-42.	0.3	52
30	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clinical Otolaryngology, 2007, 32, 337-345.	0.6	52
31	Sensitivity to radiation-induced chromosome damage may be a marker of genetic predisposition in young head and neck cancer patients. British Journal of Cancer, 2001, 84, 776-782.	2.9	51
32	Prognostic Significance of Tumor Hypoxia Inducible Factor–1α Expression for Outcome After Radiotherapy in Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1551-1559.	0.4	49
33	Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation. Radiotherapy and Oncology, 2008, 89, 105-113.	0.3	46
34	What Three Wise Men have to say about diagnosis. BMJ: British Medical Journal, 2011, 343, d7769-d7769.	2.4	45
35	IMRT dose fractionation for head and neck cancer: Variation in current approaches will make standardisation difficult. Acta OncolÃ <sup>3</sup> gica, 2009, 48, 431-439.	0.8	40
36	331 cases of clinically node-negative supraglottic carcinoma of the larynx: a study of a modest size fixed field radiotherapy approach. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1109-1115.	0.4	39

#	Article	IF	CITATIONS
37	The immunohistochemical expression of DNA-PKcs and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity. International Journal of Radiation Oncology Biology Physics, 1999, 45, 1005-1010.	0.4	37
38	Carcinoma of the oesophagus — a review of 108 cases treated by radical radiotherapy. Clinical Radiology, 1989, 40, 200-203.	0.5	34
39	Comparison of patient-reported late treatment toxicity (LENT–SOMA) with quality of life (EORTC) Tj ETQq1 I Oncology, 2010, 97, 270-275.	0.784314 0.3	rgBT /Overloo 33
40	Relative clinical influence of tumor dose versus dose per fraction on the occurrence of late normal tissue morbidity following larynx radiotherapy. International Journal of Radiation Oncology Biology Physics, 1993, 25, 23-28.	0.4	31
41	The impact of Radiotherapy on Swallowing and Speech in Patients who Undergo total Laryngectomy. Otolaryngology - Head and Neck Surgery, 2008, 139, 792-797.	1.1	31
42	A novel imaging technique for fusion of high-quality immobilised MR images of the head and neck with CT scans for radiotherapy target delineation. British Journal of Radiology, 2009, 82, 497-503.	1.0	26
43	Late radiation change in the CNS: MR imaging following gadolinium enhancement. Clinical Radiology, 1997, 52, 356-362.	0.5	25
44	Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy. European Journal of Cancer, 2009, 45, 1992-1998.	1.3	25
45	Submandibular gland carcinoma; An audit of local control and survival following adjuvant radiotherapy. Oral Oncology, 1999, 35, 187-190.	0.8	24
46	Osteoradionecrosis in Head-and-Neck Cancer Has a Distinct Genotype-Dependent Cause. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1479-1484.	0.4	24
47	Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome. Radiotherapy and Oncology, 1999, 53, 15-21.	0.3	23
48	Short Report: A Morbidity Scoring System for Clinical Oncology Practice: Questionnaires produced from the LENT SOMA scoring system. Clinical Oncology, 2002, 14, 68-69.	0.6	23
49	Quality of Life Measurement in the Head and Neck Cancer Radiotherapy Clinic: Is it Feasible and Worthwhile?. Clinical Oncology, 2003, 15, 205-210.	0.6	23
50	The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. British Journal of Cancer, 1999, 80, 1400-1404.	2.9	22
51	Evaluation of Larynx-Sparing Techniques With IMRT When Treating the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2008, 72, 617-622.	0.4	22
52	Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to Radiotherapy Led to an Observed Improvement in Survival—A Single Centre Experience and Review of the Literature. Scientific World Journal, The, 2014, 2014, 1-8.	0.8	22
53	Prognostic value of hypoxiaâ€associated markers in advanced larynx and hypopharynx squamous cell carcinoma. Laryngoscope, 2015, 125, E8-15.	1.1	22
54	Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentary. British Journal of Radiology, 2014, 87, 20140501.	1.0	21

#	Article	IF	CITATIONS
55	Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Acta Oncológica, 2015, 54, 88-98.	0.8	21
56	Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity — evaluation of late morbidity and a watch policy for the clinically negative neck. Radiotherapy and Oncology, 1996, 41, 21-29.	0.3	20
57	Benign schwannoma in paranasal sinuses: a clinico-pathological study of five cases, emphasising diagnostic difficulties. Journal of Laryngology and Otology, 2008, 122, 598-602.	0.4	20
58	Lack of Prognostic Effect of Carbonic Anhydrase-9, Hypoxia Inducible Factor-1α and Bcl-2 in 286 Patients with Early Squamous Cell Carcinoma of the Glottic Larynx Treated with Radiotherapy. Clinical Oncology, 2013, 25, 59-65.	0.6	20
59	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. Oral Oncology, 2015, 51, 508-513.	0.8	20
60	Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anti-Cancer Drugs, 2005, 16, 719-726.	0.7	19
61	Should FDG-PET scanning be routinely used for patients with an unknown head and neck squamous primary?. Journal of Laryngology and Otology, 2007, 121, 149-153.	0.4	19
62	Value of the Hospital Anxiety and Depression Scale in the follow up of head and neck cancer patients. Journal of Laryngology and Otology, 2013, 127, 285-294.	0.4	19
63	Randomized controlled trial to assess the effectiveness of a videotape about radiotherapy. British Journal of Cancer, 2001, 84, 8-10.	2.9	18
64	Collagen Vascular Diseases and Enhanced Radiotherapy-induced Normal Tissue Effects — a Case Report and a Review of Published Studies. Clinical Oncology, 2011, 23, 73-78.	0.6	17
65	An automated workflow for patient-specific quality control of contour propagation. Physics in Medicine and Biology, 2016, 61, 8577-8586.	1.6	17
66	Conventional fractionation should not be the standard of care for T2 glottic cancer. Radiation Oncology, 2017, 12, 178.	1.2	17
67	Adult nephroblastoma — Five cases treated by surgery, radiotherapy and chemotherapy. Clinical Radiology, 1987, 38, 483-486.	0.5	16
68	Tumor Epression of Major Vault Protein is an Adverse Prognostic Factor for Radiotherapy Outcome in Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 133-140.	0.4	16
69	Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 220-225.	3.3	15
70	Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 2004, 71, 81-84.	0.3	14
71	An analysis of radiotherapy in the management of 104 patients with parotid carcinoma. Clinical Oncology, 1995, 7, 16-20.	0.6	12
72	Discussion. Radiotherapy and Oncology, 1999, 51, 109-111.	0.3	12

#	Article	IF	CITATIONS
73	Spectral pattern complexity analysis and the quantification of voice normality in healthy and radiotherapy patient groups. Medical Engineering and Physics, 2004, 26, 291-301.	0.8	12
74	Synchronous Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck using Capecitabine: a Single-centre, Open-label, Single-group Phase II Study. Clinical Oncology, 2011, 23, 149-158.	0.6	12
75	Relative plan robustness of step-and-shoot vs rotational intensity–modulated radiotherapy on repeat computed tomographic simulation for weight loss in head and neck cancer. Medical Dosimetry, 2016, 41, 154-158.	0.4	12
76	Unnecessary morbidity following irradiation of lateralized head and neck carcinoma. International Journal of Radiation Oncology Biology Physics, 1993, 25, 379.	0.4	10
77	Outstanding issues in radiation dose-fractionation studies. International Journal of Radiation Biology, 1998, 73, 383-394.	1.0	10
78	Quantifying aberrant phonation using approximate entropy in electrolaryngography. Speech Communication, 2005, 47, 312-321.	1.6	10
79	Primary Radiotherapy for Carcinoma of the Retromolar Trigone: A Useful Alternative to Surgery. Clinical Oncology, 2010, 22, 119-124.	0.6	10
80	Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e373-e374.	5.1	10
81	Collective spectral pattern complexity analysis of voicing in normal males and larynx cancer patients following radiotherapy. Biomedical Signal Processing and Control, 2006, 1, 113-119.	3.5	9
82	Amoxycillin-Clavulanic Acid Combination in Bronchopulmonary Infection due to ??-Lactamase-producing Branhamella catarrhalis Preliminary Report. Drugs, 1986, 31, 113-114.	4.9	8
83	An unusual case of carotid body tumour. Clinical Oncology, 1998, 10, 62-64.	0.6	8
84	Use of multiple biological markers in radiotherapy-treated head and neck cancer. Journal of Laryngology and Otology, 2010, 124, 650-658.	0.4	8
85	Carotid dosimetry for T1 glottic cancer radiotherapy. British Journal of Radiology, 2014, 87, 20130754.	1.0	8
86	Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets. International Journal of Radiation Oncology Biology Physics, 1997, 39, 1173-1182.	0.4	7
87	Electroglottogram approximate entropy: a novel single parameter for objective voice assessment. Journal of Laryngology and Otology, 2010, 124, 520-528.	0.4	7
88	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS ONE, 2018, 13, e0194841.	1.1	7
89	Radiologically Inserted Gastrostomies: their use in Patients with Cancer of the Upper Aerodigestive Tract. Clinical Oncology, 2003, 15, 87-91.	0.6	6
90	Radical radiotherapy for early laryngeal cancer in a patient with human immunodeficiency virus: no evidence of increased toxicity. British Journal of Radiology, 2004, 77, 519-520.	1.0	6

#	Article	IF	CITATIONS
91	Aeromonas hydrophila septicaemia and muscle abscesses associated with immunosuppression. Postgraduate Medical Journal, 1988, 64, 701-702.	0.9	5
92	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. Journal of Cancer Research and Clinical Oncology, 2018, 144, 389-401.	1.2	5
93	Can Synchronous Chemotherapy be Added to Accelerated Hypofractionated Radiotherapy in Patients with Base of Tongue Cancer?. Clinical Oncology, 2010, 22, 185-191.	0.6	4
94	A comparison of cisplatin and fluorouracil alone or with docetaxel in squamous cell carcinoma of the head and neck. Nature Clinical Practice Oncology, 2008, 5, 306-307.	4.3	3
95	Economical with the radiotherapy â€~dose'. Clinical Oncology, 1992, 4, 204.	0.6	2
96	Radiobiological Modelling of UK Head and Neck Schedules — Calculation Errors. Clinical Oncology, 2007, 19, 558.	0.6	2
97	Inconsistencies in the care of head and neck cancer patients experiencing trismus. European Journal of Oncology Nursing, 2011, 15, 364.	0.9	2
98	Practice Change after Evaluation of an Offline Correction Protocol for Image-guided Radiotherapy in Head and Neck Cancer. Clinical Oncology, 2015, 27, 750-751.	0.6	2
99	Nasoethmoidal adenocarcinoma in woodworking twins. Clinical Oncology, 1990, 2, 298-299.	0.6	1
100	The explanation for the influence of prescription habits on radiation dose-time parameters for head and neck tumour control. Radiotherapy and Oncology, 1995, 34, 228-229.	0.3	1
101	Correspondence. International Journal of Radiation Oncology Biology Physics, 1999, 44, 967-968.	0.4	1
102	Barium paste: useful for primary tumour localization in oral cancer. British Journal of Radiology, 2004, 77, 143-145.	1.0	1
103	Comments on Selected Recent Dysphagia Literature. Dysphagia, 2009, 24, 249-255.	1.0	1
104	Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Chemotherapy, 2013, 59, 1-7.	0.8	1
105	Correspondence. Clinical Oncology, 1996, 8, 274-275.	0.6	0
106	Fractionation or chemoradiation for head and neck cancer?. Clinical Oncology, 1998, 10, 137.	0.6	0
107	Radiotherapy for the Treatment of Longstanding Head and Neck Hemangioma. Otolaryngology - Head and Neck Surgery, 2009, 141, 296-297.	1.1	0
108	Non-standard Radical Treatment of Skin Cancer. Clinical Oncology, 2011, 23, 493-494.	0.6	0

#	Article	IF	CITATIONS
109	Automatic Segmentation to Define Organs at Risk (OARs) for Function Sparing Head and Neck IMRT. International Journal of Radiation Oncology Biology Physics, 2014, 90, S876-S877.	0.4	0